Now weight-loss drug can ease symptoms of deadly heart failure, as findings of new trial offers hope to half a million Britons Semaglutide, marketed as Ozempic or Wegovy, helps sufferers of HFpEF By Kate Pickles For The Daily Mail Published: 22:00 BST, 23 June 2024 | Updated: 22:01 BST, 23 June 2024 e-mail View comments Weight-loss jabs can help ease symptoms of deadly heart failure, offering hope to half a million Britons. A trial found semaglutide, known under the brand names Ozempic and Wegovy, helped women lose more weight than men but provided the same benefits to members of each sex who suffer from a common type of heart failure. Experts said it suggests that it may be addressing an underlying mechanism of heart failure, in addition to the benefits of the patients’ weight loss .
The analysis is the first to look at the effects of the jab on men and women separately in relation to preserved ejection fraction (HFpEF), where the heart pumps normally but is too stiff to fill properly. The study involving 1,145 patients analysed the effects of a weekly 2.4mg jab over the course of a year.
Semaglutide, sometimes marketed as Ozempic, helps women lose more weight than men, but can help ease symptoms of preserved ejection fraction (HFpEF) Women shed more weight, losing an average of 9.6 per cent of their body weight compared to 7.2 per cent in men.
But the jabs were found to improve heart failure symptoms, such as shortness of breath, fatigue and swelling in the legs and feet,.
